Intellia Capital Expenditures from 2010 to 2025
| NTLA Stock | USD 8.16 0.57 6.53% |
Capital Expenditures | First Reported 2014-06-30 | Previous Quarter 1.3 M | Current Value 981 K | Quarterly Volatility 7 M |
Check Intellia Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intellia Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.5 M, Interest Expense of 10.3 M or Selling General Administrative of 132.1 M, as well as many indicators such as Price To Sales Ratio of 18.92, Dividend Yield of 0.0 or PTB Ratio of 2.58. Intellia financial statements analysis is a perfect complement when working with Intellia Therapeutics Valuation or Volatility modules.
Intellia | Capital Expenditures |
Latest Intellia Therapeutics' Capital Expenditures Growth Pattern
Below is the plot of the Capital Expenditures of Intellia Therapeutics over the last few years. Capital Expenditures are funds used by Intellia Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Intellia Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software. It is Intellia Therapeutics' Capital Expenditures historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Intellia Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capital Expenditures | 10 Years Trend |
|
Capital Expenditures |
| Timeline |
Intellia Capital Expenditures Regression Statistics
| Arithmetic Mean | 9,520,675 | |
| Geometric Mean | 3,559,793 | |
| Coefficient Of Variation | 148.67 | |
| Mean Deviation | 8,461,031 | |
| Median | 6,358,000 | |
| Standard Deviation | 14,154,266 | |
| Sample Variance | 200.3T | |
| Range | 58M | |
| R-Value | 0.57 | |
| Mean Square Error | 143.9T | |
| R-Squared | 0.33 | |
| Significance | 0.02 | |
| Slope | 1,707,276 | |
| Total Sum of Squares | 3005.1T |
Intellia Capital Expenditures History
About Intellia Therapeutics Financial Statements
Intellia Therapeutics stakeholders use historical fundamental indicators, such as Intellia Therapeutics' Capital Expenditures, to determine how well the company is positioned to perform in the future. Although Intellia Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Intellia Therapeutics' assets and liabilities are reflected in the revenues and expenses on Intellia Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Intellia Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Expenditures | 16.1 M | 13.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Intellia Therapeutics Correlation against competitors. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.25) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets | Return On Equity |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.